Clinical trials: Histological Type of Neoplasm
Chronic Lymphocytic Leukemia
Daratumumab and Ibrutinib in Treating Patients With Symptomatic Chronic Lymphocytic Leukemia
This phase Ib trials studies the side effects of daratumumab and ibrutinib and how well they work in treating patients with symptomatic chronic lymphocytic leukemia.
- Trial name
- NCT03447808
- Testing
- Daratumumab, Ibrutinib, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Jennifer Woyach
Melanoma
MSB0010445 and Stereotactic Body Radiation Therapy in Advanced Melanoma
This is a Phase 2a, open-label, parallel group, partly randomized dose escalation trial to assess the safety and efficacy of a low dose, an intermediate dose, and high dose MSB0010445 given by intravenous infusion to subjects…
- Trial name
- NCT01973608
- Testing
- MSB0010445 (0.3 milligram per kilogram [mg/kg]), MSB0010445 (1.0 mg/kg), MSB0010445 (1.8 mg/kg)
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- EMD Serono
Malignant Melanoma, Brain Metastases
E6201 Plus Dabrafenib for the Treatment of Metastatic Melanoma Central Nervous System Metastases (CNS)
This is a Phase 1 study of E6201 plus dabrafenib for the treatment of CNS metastases in BRAF V600-mutated metastatic melanoma. A total of up to N=28-34 subjects with melanoma metastasized to the CNS will be included.
- Trial name
- NCT03332589
- Testing
- E6201, E6201 plus dabrafenib
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Spirita Oncology, LLC
Injury; Temporal Region
Dose Constraints for the Temporal Lobes of Intensity-modulated Radiotherapy Treatment Plans for Nasopharyngeal Carcinoma
Radiation-induced temporal lobe injury (TLI) is usually devastating to patients; however, there is a poor understanding of TLI in nasopharyngeal carcinoma (NPC) patients treated with IMRT.
- Trial name
- NCT03539250
- Testing
- IMRT
- Volunteers
- 350 people
- Sponsor
- Jiangxi Provincial Cancer Hospital
Radical Cystectomy, Urothelial Carcinoma
Study of Disitamab Vedotin Combined With Gemcitabine in Neoadjuvant Treatment of Urothelial Carcinoma
A multicenter, open, single arm, phase II clinical trial was designed for myometrial invasive bladder cancer to evaluate the efficacy and safety of RC48-ADC combined with gemcitabine in preoperative neoadjuvant treatment of MIBC…
- Trial name
- NCT05723991
- Testing
- Disitamab Vedotin and Gemcitabine
- Where
- 2 sites in China
- Volunteers
- 36 people
- Sponsor
- Chunguang yang (101937)
Carcinoma, Pancreatic Ductal
Organochlorine Concentration in Adipose Tissue and Pancreatic Adenocarcinoma
Pancreatic adenocarcinoma represents more than 90% of pancreatic neoplasms. Around 14000 new cases of pancreatic adenocarcinoma are being diagnosed each year in France and about 8.6% in Grand Est region.
- Trial name
- PESTIPAC (NCT04429490)
- Testing
- Adipose tissue sampling during surgery and urine sampling
- Where
- France
- Volunteers
- 56 people
- Sponsor
- CHU de Reims
Recurrent High Grade Glioma
Recurrent High Grade Glioma Treated by LITT
This clinical trial aims to investigate the efficiency and safety of laser interstitial thermal therapy (LITT) in recurrent high-grade glioma (rHGG) patients.
- Trial name
- REGALITT (NCT06161610)
- Testing
- LITT, Control
- Where
- 9 sites in China
- Volunteers
- 135 people
- Sponsor
- Beijing Tiantan Hospital
Adult Acute Promyelocytic Leukemia (M3), Blastic Phase Chronic Myelogenous Leukemia
BMS-214662 in Treating Patients With Acute Leukemia, Myelodysplastic Syndrome, or Chronic Myeloid Leukemia
Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Phase I trial to study the effectiveness of BMS-214662 in treating patients who have acute leukemia, myelodysplastic…
- Conditions
- Adult Acute Promyelocytic Leukemia (M3), Blastic Phase Chronic Myelogenous Leukemia, Childhood Myelodysplastic Syndromes, Previously Treated Myelodysplastic Syndromes
- Trial name
- NCT00006213
- Testing
- BMS-214662, pharmacological study, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
Marginal Zone Lymphoma
A Study of Ibrutinib With Rituximab in People With Untreated Marginal Zone Lymphoma
The purpose of this study is to see if the combination of rituximab and ibrutinib can help people with marginal zone lymphoma who have not received treatment in the past.
- Trial name
- NCT04212013
- Testing
- Ibrutinib, Rituximab
- Where
- 10 sites in United States
- Volunteers
- 23 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Metastatic Melanoma, Nausea
Nausea and Vomiting In Patients Receiving Consecutive Days of Cisplatin
The purpose of this study is to observe the incidence of nausea with systemic chemotherapy that includes consecutive days (more than one day)of cisplatin medication.
- Trial name
- NCT00716560
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Chronic Myeloid Leukemia
2nd or 3rd TKI-stop After 2 Years Nilotinib Pre-treatment in CML-patients
The main goal of the study is the assessment of duration of major molecular response (MMR) or better at 12 and 36 months after stopping tyrosine kinase inhibitors (TKI) therapy a second or third time in patients with at least…
- Trial name
- NAUT (NCT02917720)
- Testing
- TKI discontinuation, nilotinib
- Where
- 15 sites in Germany, Netherlands
- Volunteers
- 75 people
- Sponsor
- European LeukemiaNet
Rhabdomyosarcoma, Malignant Peripheral Nerve Sheath Tumors
Trial of Dasatinib in Advanced Sarcomas
This study will examine the response rate and the 6-month progression-free survival rates of subjects with advanced sarcoma treated with dasatinib.
- Conditions
- Rhabdomyosarcoma, Malignant Peripheral Nerve Sheath Tumors, Chondrosarcoma, Sarcoma, Ewing's
- Trial name
- NCT00464620
- Testing
- Dasatinib
- Where
- 20 sites in United States
- Volunteers
- 366 people
- Sponsor
- Sarcoma Alliance for Research through Collaboration
Carcinoma, Hepatocellular, Survival Rate
Resection Versus Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma With Solitary Huge Tumor
This clinical trial aims to compare hepatectomy with Transarterial Chemoembolization (TACE) for Hepatic Cellular Cancer With Solitary Huge Tumor (≥5cm).
- Trial name
- NCT03191123
- Testing
- hepatic resection, TACE
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Huazhong University of Science and Technology
Squamous Cell Carcinoma of the Oropharynx, HPV
Reduced-intensity Therapy for Oropharyngeal Cancer in Non-smoking HPV-16 Positive Patients
Taking into account the excellent prognosis of patients with HPV-positive oropharyngeal cancer with < 10 pack-year smoking, the investigators hypothesize that reducing the intensity of therapy for these patients will reduce…
- Trial name
- NCT01663259
- Testing
- Cetuximab, Radiotherapy
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- University of Michigan Rogel Cancer Center
Uterine Fibroids, Endometriosis
Pharmacokinetics and Safety of Vilaprisan in Renal Impairment
The purpose of the study is to evaluate the pharmacokinetics of vilaprisan in subjects with moderate to severe renal impairment compared with matched subjects with normal renal function.
- Trial name
- NCT03411980
- Testing
- Vilaprisan (BAY1002670)
- Where
- 2 sites in United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Bayer
Ovarian Cancer
Early Detection of Ovarian Cancer: GC/FT-ICR Mass Spectrometry and Canine Olfaction
RATIONALE: Studying samples of exhaled breath from patients with ovarian epithelial cancer, polycystic ovarian syndrome, or endometriosis and from healthy participants in the laboratory may help doctors identify and learn more…
- Trial name
- NCT00757952
- Testing
- Fourier transform ion cyclotron resonance mass spectrometry, chromatography, diagnostic laboratory biomarker analysis
- Where
- 4 sites in United States
- Volunteers
- 109 people, healthy volunteers welcome
- Sponsor
- Pine Street Foundation
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, Myeloid, Acute
Bone Marrow Transplant From Partially Matched Donors and Nonmyeloablative Conditioning for Blood Cancers (BMT CTN 0603)
Bone marrow transplants are one treatment option for people with leukemia or lymphoma. Family members or unrelated donors with a similar type of bone marrow usually donate their bone marrow to the transplant patients.
- Conditions
- Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, Myeloid, Acute, Burkitt Lymphoma, Lymphoma, B-Cell
- Trial name
- NCT00849147
- Testing
- Haploidentical Bone Marrow Transplantation, GVHD prophylaxis
- Where
- 17 sites in United States
- Volunteers
- 55 people
- Sponsor
- Medical College of Wisconsin
Cutaneous Melanoma, Stage IV, BRAF V600 Mutation
Advanced Melanoma in Russian Experience
Retrospective chart review Study of patients with BRAF V600 positive advanced (unresectable or metastatic) melanoma, who were treated with targeted therapy in routine clinical practice in Russian Federation
- Trial name
- ADMIRE (NCT03663647)
- Where
- 11 sites in Russia
- Volunteers
- 382 people
- Sponsor
- MelanomaPRO, Russia
Locally Advanced and/or Metastatic Anaplastic Large Cell Lymphoma, Locally Advanced and/or Metastatic Inflammatory Myofibroblastic Tumor
CREATE: Cross-tumoral Phase 2 With Crizotinib
The study will primarily assess the antitumor activity of crizotinib in a variety of tumors with alterations in ALK and/or MET pathways.
- Conditions
- Locally Advanced and/or Metastatic Anaplastic Large Cell Lymphoma, Locally Advanced and/or Metastatic Inflammatory Myofibroblastic Tumor, Locally Advanced and/or Metastatic Papillary Renal Cell Carcinoma Type 1, Locally Advanced and/or Metastatic Alveolar Soft Part Sarcoma
- Trial name
- CREATE (NCT01524926)
- Testing
- Crizotinib (PF-02341066)
- Where
- 25 sites in Belgium, France and 8 more
- Volunteers
- 582 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Lymphoma, Large B-Cell, Diffuse, Lymphoma, Non-Hodgkin
A Phase 1b Open-label Study to Evaluate the Safety and Efficacy of CC-122 With Obinutuzumab (GA101) in Relapsed/Refractory DLBCL and iNHL.
CC-122-NHL-001 study is a multicenter, open-label, phase Ib study with dose escalation and expansion parts. It evaluates the safety, tolerability and clinical pharmacokinetics of CC-122 in combination with obinutuzumab (GA101).
- Trial name
- NCT02417285
- Testing
- Obinutuzumab, CC-122
- Where
- 8 sites in France, Italy and 1 more
- Volunteers
- 75 people
- Sponsor
- Celgene
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.